CEO Total Pay
$19.8M
FY2021 Summary Compensation, well above median
SRNE FY2021 SEC EDGAR DEF 14A
Sorrento Therapeutics, Inc. CEO pay ratio
The CEO earned $19.8M in FY2021 against median worker pay of $130,192 · Chemicals & Pharmaceuticals.
- State
- DE
- Filing date
- 2022-11-01
- Industry
- Chemicals & Pharmaceuticals
- Fiscal year
- FY2021
Data updated August 2026
Subscribe to Sorrento Therapeutics, Inc. CEO pay filing updates (RSS)
CEO-to-worker pay ratio
152:1
High (Scale: 0–1000:1)
CEO pay
$19.8M
Median worker
$130,192
Latest filing FY2021. This company's newest DEF 14A on file is for FY2021, not FY2025, so the figures on this page are from that earlier year and are not ranked against the FY2025 industry benchmark. Industry pages mark issuers like this one with a "Latest filing" label.
Answer first
Sorrento Therapeutics, Inc. reported a 152:1 CEO-to-worker pay ratio in FY2021 - above the Chemicals & Pharmaceuticals median of 42:1 across 168 filers.
Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.
- Pay ratio
- 152:1
- FY2021 disclosed
- CEO total
- $19.8M
- Summary Compensation Table total
- Median worker
- $130,192
- Dodd-Frank median employee
Ratio bands among Chemicals & Pharmaceuticals peers
Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.
CEO Compensation Breakdown, FY2021
A component-level pay breakdown is not reported in Sorrento Therapeutics, Inc.'s structured SEC pay-ratio disclosure. See our methodology →
Industry Comparison - Chemicals & Pharmaceuticals
This Company's Ratio
152:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$19.8M
Companies in Industry
168
vs. Industry Median
Above
Sorrento Therapeutics, Inc.: STEEP · PEAK pay ratio
Sorrento Therapeutics, Inc. disclosed 152:1 CEO-to-worker pay and $19.8M CEO total in FY2021. the CEO earned 152× the median employee ($130,192) in FY2021.
Median employee $130,192 (ELITE-MED); STEEP · PEAK stamps put about 152 median-wage years per CEO year.
Pay Ratio
152:1
Elevated vs. peers
What FY2021 shows for Sorrento Therapeutics, Inc.
Sorrento Therapeutics, Inc. disclosed 152:1 CEO-to-worker pay and $19.8M CEO total in FY2021. The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Sorrento Therapeutics, Inc.'s $19.8M CEO total is above the $7.9M industry median CEO pay.
Sorrento Therapeutics, Inc. stamps STEEP · PEAK · ELITE-MED; grant-date fair value (not realized pay) is what the DEF 14A reports. Open Chemicals & Pharmaceuticals peers.
Key Data, FY2021
- Total Compensation
- $19.8M
- Median Employee Pay
- $130,192
- Pay Ratio
- 152:1
- Filing Date
- 2022-11-01
Company Info
- Ticker
- SRNE
- CIK
- 850261
- Industry
- Chemicals & Pharmaceuticals
- SIC Code
- 2836
- State
- DE
SEC EDGAR DEF 14A for CIK 850261, FY2021. Informational only, not investment advice. Verify on EDGAR.
Read our methodology - how this data is sourced, computed, and verified. Sorrento Therapeutics, Inc. disclosed 152:1 CEO-to-worker pay and $19.8M CEO total in FY2021.
Read with Sorrento Therapeutics, Inc.
ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps STEEP · PEAK · ELITE-MED.
Bristol Myers Squibb Co · PEAK
ABS(ceo_total_comp) peer at $19.8M (Δ $7K lighter vs Sorrento Therapeutics, Inc.); MID · ELITE-MED vs this page's STEEP · PEAK · ELITE-MED.
Sabre Corp · PEAK
ABS(ceo_total_comp) peer at $19.8M (Δ $11K heavier vs Sorrento Therapeutics, Inc.); STEEP · HIGH-MED vs this page's STEEP · PEAK · ELITE-MED.
Prudential Financial Inc · PEAK
ABS(ceo_total_comp) peer at $19.8M (Δ $32K heavier vs Sorrento Therapeutics, Inc.); STEEP · HIGH-MED vs this page's STEEP · PEAK · ELITE-MED.
Cigna Group · PEAK
ABS(ceo_total_comp) peer at $19.9M (Δ $95K heavier vs Sorrento Therapeutics, Inc.); STEEP · PAR-MED vs this page's STEEP · PEAK · ELITE-MED.
Chemicals & Pharmaceuticals benchmark
Sorrento Therapeutics, Inc. stamps STEEP · PEAK · ELITE-MED inside SIC 28 - open the industry median board after the ABS peers.
Pay-ratio rankings · STEEP
See where STEEP · PEAK packages sit on the national leaderboard after reading Sorrento Therapeutics, Inc..
Comp structure · PEAK
Sorrento Therapeutics, Inc.'s PEAK CEO total is equity-sensitive - read what grant-date fair value does and does not mean.
Data sourced from SEC EDGAR DEF 14A for Sorrento Therapeutics, Inc. (CIK 850261), FY2021. See our methodology. Aggregated by PlainCEOPay as of August 2026.
Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.